期刊文献+

抗PD-1/PD-L1免疫疗法联合同步放化疗治疗局部晚期宫颈癌的临床效果 被引量:3

Clinical effect of anti-PD-1/PD-L1 immunotherapy combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer
原文传递
导出
摘要 目的探讨抗程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)免疫疗法联合同步放化疗治疗局部晚期宫颈癌(LACC)的临床效果。方法回顾性选取2018年11月至2019年10月在秦皇岛市第一医院接受抗PD-1/PD-L1免疫疗法(帕博利珠单抗)联合同步放化疗[调强放疗(IMRT)+TP(紫杉醇+卡铂)化疗]治疗的LACC患者51例作为观察组,选取同期接受同步放化疗治疗的51例LACC患者作为对照组。比较两组客观缓解率、疾病控制率、肿瘤标志物[鳞状细胞癌抗原(SCCAg)、可溶性细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)]、增殖凋亡指标[存活素(Survivin)、B淋巴细胞瘤-2基因(Bcl-2)、半胱氨酸蛋白酶-3(Caspase-3)、细胞凋亡促进物质(Bax)]、PD-1/PD-L1[可溶性PD-L1(sPD-L1)、CD4^(+)T细胞表面PD-1表达(PD-1 CD4^(+)T细胞)、CD8^(+)T细胞表面PD-1表达(PD-1 CD8^(+)T细胞)及CD14^(+)单核细胞表面PD-L1表达(PD-L1 CD14^(+)单核细胞)]、安全性及1年内生存率。结果(1)疾病控制及安全性:观察组客观缓解率、疾病控制率分别为80.39%(41/51)、92.16%(47/51),高于对照组的39.22%(20/51)、70.59%(36/51)(均P<0.05),但组间各毒副反应发生率差异均无统计学意义(均P>0.05);(2)肿瘤标志物及增殖凋亡指标:与治疗前比较,治疗后两组血清SCCAg、CYFRA21-1、CEA、CA125水平及Survivin、Bcl-2水平均显著降低,Caspase-3、Bax水平显著升高,且治疗后观察组以上指标均优于对照组(均P<0.05);(3)PD-1/PD-L1:治疗后,观察组sPD-L1、PD-1 CD4^(+)T细胞、PD-1 CD8^(+)T细胞、PD-L1 CD14^(+)单核细胞较治疗前显著降低(均P<0.05),且观察组sPD-L1、PD-1 CD4^(+)T细胞、PD-1 CD8^(+)T细胞、PD-L1 CD14^(+)单核细胞均低于对照组(均P<0.05);(4)生存情况:观察组1年内生存率高于对照组(P<0.05)。结论抗PD-1/PD-L1免疫疗法联合同步放化疗治疗LACC临床效果显著,可通过调控肿瘤标志物、增殖凋亡指标及PD-1/PD-L1表达来有效抑制病情进展,且不增加治疗风险,对提升患者生存率具有积极作用。 Objective To investigate the clinical effect of programmed death receptor-1(PD-1)/programmed death receptor ligand-1(PD-L1)immunotherapy combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer(LACC).Methods From November 2018 to October 2019,51 LACC patients in Qinhuangdao First Hospital who received anti-PD-1/PD-L1 immunotherapy(pembrolizumab)combined with concurrent radiotherapy and chemotherapy[intensity modulated radiotherapy(IMRT)+TP(taxol+carboplatin)chemotherapy]were selected as the observation group.51 LACC patients who received concurrent chemotherapy and radiotherapy were selected as the control group.The objective remission rate,disease control rate,tumor markers[squamous cell carcinoma antigen(SCCAg),soluble cytokeratin 19 fragment(CYFRA21-1),and carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],proliferation and apoptosis indicators[survivin(Survivin),B-cell lymphoma-2(Bcl-2),Caspase-3(Caspase-3),apoptosis-promoting substance(Bax)],PD-1/PD-L1[soluble PD-L1(sPD-L1),CD4^(+)T cell surface PD-1 expression(PD-1 CD4^(+)T cells),CD8^(+)T cell surface PD-1 expression(PD-1 CD8^(+)T cell)and CD14^(+)monocyte surface PD-L1 expression(PD-L1 CD14^(+)monocyte)],safety and survival rate within 1 year were compared between the two groups.Results(1)Disease control and safety:the objective response rate and disease control rate of the observation group were 80.39%(41/51)and 92.16%(47/51),respectively,which were higher than those of the control group by 39.22%(20/51)and 70.59%(36/51)(all P<0.05),but there was no significant difference in the incidence of side effects between the groups(all P>0.05).(2)Tumor markers and proliferation and apoptosis indexes:compared with those before treatment,the levels of serum SCCAg,CYFRA21-1,CEA,CA125,survivin and Bcl-2 in the two groups after treatment were significantly lower,and the levels of Caspase-3 and Bax were significantly higher;the above indexes in the observation group were better than those in the control group after treatment(all P<0.05).(3)PD-1/PD-L1:after treatment,sPD-L1,PD-1 CD4^(+)T cells,PD-1 CD8^(+)T cells and PD-L1 CD14^(+)monocytes in the observation group were significantly lower than those before treatment(all P<0.05).After treatment,the sPD-L1,PD-1 CD4^(+)T cells,PD-1 CD8^(+)T cells,PD-L1 CD14^(+)monocytes in the observation group were lower than those in the control group(all P<0.05).(4)Survival:the survival rate of the observation group was higher than that of the control group within 1 year(P<0.05).Conclusions The clinical effect of anti-PD-1/PD-L1 immunotherapy combined with concurrent radiotherapy and chemotherapy in the treatment of LACC is significant.It can effectively inhibit the progression of the disease by regulating tumor markers,proliferation and apoptosis indicators and PD-1/PD-L1 expression without increasing the risk of treatment,and has a positive effect on improving the survival rate of patients.
作者 邵莎莎 曹丽艳 王光霞 付宝红 付占昭 Shao Shasha;Cao Liyan;Wang Guangxia;Fu Baohong;Fu Zhanzhao(Department of Oncology,the First Hospital of Qinhuangdao,Qinhuangdao 066000,China)
出处 《中国医师杂志》 CAS 2022年第6期916-921,共6页 Journal of Chinese Physician
关键词 宫颈肿瘤 化放疗 免疫疗法 程序性细胞死亡受体1 生物标记 肿瘤 Uterine cervical neoplasms Chemoradiotherapy Immunotherapy Programmed cell death 1 receptor Biomarkers,tumor
  • 相关文献

参考文献18

二级参考文献127

  • 1李球兵,刘飒,王红阳,韩晓庆,张盼盼.复方丹参滴丸联合呼吸操对慢性阻塞性肺疾病患者疗效及凝血功能的影响[J].实用老年医学,2013,27(8):670-672. 被引量:9
  • 2陈涛利,卞翠翠,杨雷,刘子玲.早期高危宫颈癌患者术后不同治疗方案的临床疗效[J].中国老年学杂志,2015,35(1):55-57. 被引量:25
  • 3卞美璐.WHO(2006年)宫颈癌综合防治实践指南简介[J].中国实用妇科与产科杂志,2007,23(7):557-560. 被引量:106
  • 4Eddy GL, Bundy BN, Creasman WT, et al. Treatment of ( " bulk- y") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hyster-ectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group[ J]. Gynecol Onco1,2007,106 (2) :362-369.
  • 5Wen H, Wu X, Li Z, et al. A prospective randomized controlled study on multiple neoadjuvant treatments for patients with stage IB2 to IIA cervical cancer[ J]. Int J Gynecol Cancer, 2012,22 (2) :296-302. DOI: 10. 1097/IGC. 0b013e31823610al.
  • 6Kim HS, Kim JY, Park NH, et al. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IBI-IIA cervical cancer[ J ]. Gynecol Oncol, 2010,119 (2) : 217-224. DOI: 10. 1016/j. ygyno. 2010.06. 017.
  • 7Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer [J]. J Obstet Gynaecal Res, 2006, 32(3) : 315-323.
  • 8Chen H, Liang C, Zhang L, et al. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: A randomized study [J]. Gynecol Oncol, 2008,110(3) :308-315. DOI: 10. 1016/j. ygyno. 2008.05. 026.
  • 9Lee JY, Kim YH, Kim MJ, et al. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadju- vant chemotherapy followed by radical hysterectomy and primary radical hysterectomy[ J ]. Arch Gyneeol Obstet, 2011,284 ( 2 ) : 477-482. DOI: 10. 1007/s00404-010-1685-9.
  • 10Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III ran- domised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, II3.2, and liB cer- vical cancer: a Japan Clinical Oncology Group trial (JCOG 0102) [J]. Br J Canoer,2013,28; 108 (10) : 1957-1963. DOI: 10. 1038/bjc. 2013. 179.

共引文献154

同被引文献33

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部